The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Relax, we get a deal ....good news.
We dont get a deal, who cares, as the business is performing well (find out tomorrow)
Another extension, again who cares (although I think this is holding the SP back)
Which ever way you cut the cake value will out in the end....
Deeko, one thing you are missing, in your rose coloured view and why the SP has tanked
"There have been delays and cost overruns which together have had a significant negative impact on the joint venture's projected working capital. After the period end, Longboat JAPEX drew down US$17 million "
So the 600 bopd have cost 17m.....so far